Publications

Hot Flashes

1st publication SGB for hot flashes – https://dreugenelipov.com/wp-content/uploads/2023/06/2005-hot-flashes.pdf

Lancet Oncology 2008 Pilot study – https://dreugenelipov.com/wp-content/uploads/2026/07/oncology-grapgh.pdf

Lancet Oncology follow up – https://dreugenelipov.com/wp-content/uploads/2023/06/lancet-follow-up.pdf

Stellate ganglion block (SGB) to treat perimenopausal hot flashes: Clinical evidence and neurobiology – https://www.maturitas.org/article/S0378-5122(11)00043-0/abstract

Hot flashes (HF) are the most common symptom of menopause, affecting approximately 80% of perimenopausal women in Western societies [1]. Their effects are even more acute and debilitating among breast cancer survivors. In addition, women with most breast cancers are often prescribed estrogen-blocking medication to reduce the likelihood of recurrence. For instance, tamoxifen (TAM) taken over 5years will significantly reduce breast cancer recurrence [2]. Unfortunately, the literature shows that within 180days of starting treatment with TAM, more than 50% of women discontinue the drug [2], mainly due to the severity of their HF [2]. For these women, the risk of cancer recurrence is more tolerable than enduring their acute vasomotor instability. While hormone replacement therapy (HRT) is the most effective treatment for HF, its use declined rapidly following the release of data from the Women’s Health Initiative indicating increased risk of cardiovascular disease and breast cancer, among other findings [3]. Further, the use of HRT is clearly contraindicated for most breast cancer survivors due to increased recurrence risk. Alternatives to HRT include acupuncture, environmental cooling, hypnosis and other non-hormonal “natural” or “bio-identical” remedies, yet their efficacy is disappointing [4]. Thus, millions of American women await the arrival of new options to provide effective relief for perimenopausal hot flashes.

Non lipov articles​

Cleveland Clinic Journal of Medicine 2022 – https://dreugenelipov.com/wp-admin/post.php?post=5062&actiohttps://www.ccjm.org/node/11322?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Cleveland_Clinic_Journal_of_Medicine_TrendMD_1n=elementor

ABSTRACT – Vasomotor symptoms, also called hot flashes, hot flushes, and night sweats, are common during the menopause transition. Severe symptoms can substantially decrease quality of life. The authors first review current hormonal and nonhormonal therapies, then review evidence supporting the potential use of stellate ganglion block for managing vasomotor symptoms in perimenopausal and postmenopausal women.

Cancer Research – https://aacrjournals.org/cancerres/article/69/24_Supplement/809/551346/​

Conclusion: This pilot and prospectively planned study to test efficacy of GSB on hot flushes and/or night sweats confirmed that breast cancer patients suffering from invalidating symptoms may benefit with no short term harm. Further results of the patients in both studies will be presented during the meeting. This will also answer the question whether long term efficacy remains.

Mayo Clinic – https://link.springer.com/article/10.1007/s00520-010-0907-9

• Pilot evaluation of a stellate ganglion block for the treatment of hot flashes​
• 2009 ​
• Conclusions​
• The results of this pilot trial support that stellate ganglion blocks may be a helpful therapy for hot flashes. A prospectiveplacebo-controlled clinical trial should be done to more definitively determine this contention.​

Northwestern University – https://journals.lww.com/menopausejournal/abstract/10.1097/gme.0000000000000194~effects-of-stellate-ganglion-block-on-vasomotor-symptoms

Conclusions​ – SGB may provide effective treatment of VMS in women who seek nonhormonal treatments because of safety concerns and personal preference. The finding that SGB significantly reduces objectively measured VMS provides further evidence of efficacy. A larger trial is warranted to confirm these findings.​